Chemotherapy-induced cognitive impairment (CICI): An overview of etiology and pathogenesis
- PMID: 32673664
- DOI: 10.1016/j.lfs.2020.118071
Chemotherapy-induced cognitive impairment (CICI): An overview of etiology and pathogenesis
Abstract
Many cancer patients treated with chemotherapy develop chemotherapy-induced cognitive impairment (CICI), often referred to as chemo-brain, which manifest during or post-treatment with variable degrees, onset and duration thereby affecting the patients' quality of life. Several chemotherapeutic agents have been studied to determine its possible association with cognitive impairment and to fully comprehend their contribution to CICI. A vast number of studies have emerged proposing several candidate underlying mechanisms and etiologies contributing to CICI such as direct neurotoxicity, BBB disruption, decreased hippocampal neurogenesis, white matter abnormalities, secondary neuro-inflammatory response and increased oxidative stress; however, the exact underlying mechanisms are still not well defined. This review summarizes CICI associated with most commonly used chemotherapeutic agents with emphasizes the possible underlying pathogenesis in both animal and clinical studies.
Keywords: Chemotherapy; Cognitive impairment; Immunotherapy; Neuroinflammation.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no conflicts of interest.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
